Russian Pharmaceutical Industry Leader
19.05.2022
Russian drug registered in the Dominican Republic for the first time
Russian drug registered in the Dominican Republic for the first time
On May 17, the Dominican health regulatory authority issued a marketing authorization for Bicalutamide (INN Bicalutamide).

The drug manufactured by Pharmasyntez-Nord and used to treat prostate cancer became the first Russian drug to receive marketing authorization in the Dominican Republic.

Demand for the drug in the vast market of Latin America may be explained by high quality of the product, which is manufactured using state-of-the-art equipment under strict control in accordance with the requirements of Good Manufacturing Practice of the Russian Federation at the facilities of Pharmasyntez-Nord in St. Petersburg. Therefore, it is in demand in the vast market of Latin America.

At the moment Pharmasyntez is the first and only Russian pharmaceutical company preparing to export drugs to the Dominican Republic.

Subscribe to the email newsletter about Pharmasyntez